ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas-Reference-Cited by-同舟云学术

ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas

Published:2012-10-19 Issue:3 Volume:26 Page:428-434
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Werner Henrica M J,Berg Anna,Wik Elisabeth,Birkeland Even,Krakstad Camilla,Kusonmano Kanthida,Petersen Kjell,Kalland Karl H,Oyan Anne M,Akslen Lars A,Trovik Jone,Salvesen Helga B

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2012174.pdf

Reference24 articles.

1. Abeler VM, Kjorstad KE . Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991;67:3093–3103.

2. Amant F, Moerman P, Neven P et al. Endometrial cancer. Lancet 2005;366:491–505.

3. Jones S, Wang TL, Shih Ie M et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228–231.

4. Wiegand KC . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532–1543.

5. Reisman D, Glaros S, Thompson EA . The SWI/SNF complex and cancer. Oncogene 2009;28:1653–1668.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epithelial tumors of the ovary: A review focusing on carcinoma and recent advances;Human Pathology Reports;2024-09

2. Prognostic role of transcription factorARID1Ain patients with endometrial cancer of no specific molecular profile (NSMP) subtype;International Journal of Gynecologic Cancer;2024-03-19

3. Biomarkers in the Diagnosis of Endometrial Precancers. Molecular Characteristics, Candidate Immunohistochemical Markers, and Promising Results of Three-Marker Panel: Current Status and Future Directions;Cancers;2024-03-15

4. Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer—Genetic Instability and Clinical Implications;Cells;2024-02-15

5. ARID1 and BRG1 Expression in Endometrial Cancer;In Vivo;2024